Academic literature on the topic 'Lurasidone Hcl'

This research is mainly focused on development of an Excellent Gradient method by reverse phase - high performance liquid chromatography (RP-HPLC) using UV Visible Detector. The main objective of method validation of Lurasidone HCl as a tablet dosage form is to validate the method as in-house method. As this tablet dosage form is not registered in any of Pharmacopeia, so the method is developed and validated for further studies. The sample is analyzed by RP-HPLC using octadecylsilane (C18) column (Inertsil LC-GC) as stationary phase with UV-Visible detector. The 'Gradient Method' is used as instrumental method. The Mobile phase (A) was prepared using potassium phosphate buffer by adjusting the pH of value 4.0 and mobile phase (B) was 100% acetonitrile; the ratio used for gradient was buffer: acetonitrile (40:60) respectively. The wavelength for λ max was selected by UV-Visible detector on spectrophotometer at wavelength 254nm. This method complies with Linearity , Accuracy , Recovery , Specificity , precision , stability , LOD , LOQ and Robustness.

This research is mainly focused on development of an Excellent Gradient method by reverse phase - high performance liquid chromatography (RP-HPLC) using UV Visible Detector. The main objective of method validation of Lurasidone HCl as a tablet dosage form is to validate the method as in-house method. As this tablet dosage form is not registered in any of Pharmacopeia, so the method is developed and validated for further studies. The sample is analyzed by RP-HPLC using octadecylsilane (C18) column (Inertsil LC-GC) as stationary phase with UV-Visible detector. The 'Gradient Method' is used as instrumental method. The Mobile phase (A) was prepared using potassium phosphate buffer by adjusting the pH of value 4.0 and mobile phase (B) was 100% acetonitrile; the ratio used for gradient was buffer: acetonitrile (40:60) respectively. The wavelength for λ max was selected by UV-Visible detector on spectrophotometer at wavelength 254nm. This method complies with Linearity , Accuracy , Recovery , Specificity , precision , stability , LOD , LOQ and Robustness 

The RP-HPLC were developed and validated for the estimation of lurasidone HCl as per ICH guidelines. A simple, fast, accurate and precise RP-HPLC method was developed by using methanol: water containing 0.01% ortho phosphoric acid in the ratio of 70:30 (V/V). The method was developed in Eclipse C18 column (100 mm × 4.6 mm, 3.5 μm particle size). The method was found to be linear in the range of 2.5- 15µg/mL with a correlation coefficient value of 0.999. The accuracy studies of RP-HPLC method was performed at three different levels, i.e., 50%, 100%, and 150% and recovery was found to be in the range of 100.1-100.6% .The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.30-0.92. Satisfactory validation was also obtained from recovery (99.8%) studies, intra-day and interday precision and robustness 2%. The proposed method was found to be accurate, precise and rapid for the analysis of lurasidone.

The present work communicates the selective quantification of a genotoxic impurity (P-LUH) and lurasidone hydrochloride (LUH) related compounds (I1-LUH, I2-LUH and I3-LUH) as potential impurities in the LUH active therapeutic ingredient using novel stability-indicating technique-based HPLC approach. The P-LUH, I1-LUH, I2-LUH and I3-LUH were separated on column Inerstil ODS 3V having length size of 250 mm, identification value of 4.6 mm and particle dimension of 5 μm. After that, a high sensitivity PDA detector at 231 nm was used to detect the signal of impurities. The method was thoroughly validated and established to be accurate and also precise with a rectilinear concentration range of 0.01% to 0.18% for P-LUH, 0.03% to 0.18% for I1-LUH, 0.033% to 0.18% for I2-LUH, 0.031% to 0.18% for I3-LUH and 0.03% to 0.12% for LUH with regard to a 10 μL injection. The LUH sample was exposed to UV-visible light open/closed conditions, heat for 10 days, relative humidity for 10 days, 4 N HCl for 3 days, 4 N NaOH for 1 h, 6% peroxide for 7 h, Milli Q water for 88 h and to 0.05 M Cu2+ for 88 h. The LUH was satisfactorily determined in the existence of degradation products including impurities, the LUH was satisfactorily determined. The formation of P-LUH, I1-LUH, I2-LUH and I3-LUH during degradation studies on LUH was also studied. The P-LUH, I1-LUH, I2-LUH and I3-LUH were effectively determined in LUH batches and the findings indicated the use of a novel stability-indicating technique-based HPLC approach for the selective assessment of trace impurities in LUH drug substances.

The prevalence rate is that individuals with schizophrenia and schizoaffective disorder have more than twice the risk of developing type 2 diabetes mellitus (T2DM) compared to the general population. People on the schizophrenia spectrum are genetically predisposed to type II diabetes, accompanied by weight gain as a side effect of treatment, which is a risk factor for developing type 2 diabetes, which will worsen medical outcomes and mortality rates. This literature review involves 21 journal and book literature from the last 10 years regarding schizoaffective with comorbid diabetes mellitus. Different data sources and manual literature search methods were used to find related articles. The increase in comorbid DM in schizoaffective is related to mitochondrial dysfunction, the presence of shared susceptibility genes, and side effects of therapy. Functional proteins translated from shared genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through several key cascades. Quetiapine, Ziprasidone, aripiprazole, and lurasidone have a lower metabolic risk profile. Olanzapine, clozapine and valproate are a high risk group for metabolic disorders. A much lower risk of DM was associated with lithium, lamotrigine, oxcarbazepine and bupropion monotherapy, single class selective serotonin reuptake inhibitor (SSRI) therapy and some drug combinations containing bupropion and SSRIs. Rational use of antipsychotics, metabolic monitoring and pharmacological and lifestyle modifications can also be carried out to reduce the risk of DM. Psychosis is a known risk factor for increasing metabolic syndrome. The existence of shared susceptibility genes between schizophrenia and DM, mitochondrial dysfunction, side effects of antipsychotic medication, antidepressants, mood stabilizers play a role in this. ABSTRAKAngka prevalensi individu penderita skizofrenia dan gangguan skizoafektif mempunyai risiko lebih dari dua kali lipat mengalami diabetes melitus tipe 2 (DMT2) dibandingkan populasi umum. Orang dengan spektrum skizofrenia secara genetik cenderung mengalami diabetes tipe II disertai peningkatan berat badan sebagai efek samping pengobatan merupakan faktor risiko berkembangnya diabetes tipe 2 yang akan memperburuk luaran medis dan tingkat mortalitas. Tinjauan literatur ini melibatkan 21 literatur jurnal dan buku 10 tahun terakhir mengenai skizoafektif dengan komorbiditas diabetes melitus. Sumber data yang berbeda dan metode pencarian literatur manual digunakan untuk menemukan artikel yang berkaitan. Peningkatan komorbid DM pada skizoafektif berkaitan dengan disfungsi mitokondria, adanya gen kerentanan bersama, serta efek samping terapi. Protein fungsional yang ditranslasi dari gen kerentanan genetik bersama diketahui mengatur perkembangan saraf di otak dan insulin di pankreas melalui beberapa kaskade utama. Quetiapine, Ziprasidone, aripiprazole, dan lurasidone memiliki profil risiko metabolik yang lebih rendah. Olanzapine, clozapine dan valproat merupakan kelompok risiko tinggi terjadinya gangguan metabolisme. Risiko DM jauh lebih rendah dikaitkan dengan monoterapi litium, lamotrigin, oxcarbazepine dan bupropion, terapi kelas tunggal inhibitor reuptake serotonin selektif (SSRI) dan beberapa kombinasi obat yang mengandung bupropion dan SSRI. Penggunaan antipsikotik yang rasional, pemantauan metabolik serta modifikasi farmakologis dan gaya hidup juga dapat dilakukan untuk mengurangi risiko DM. Psikosis merupakan faktor risiko yang diketahui meningkatkan sindrom metabolik. Adanya gen kerentanan bersama antara skizofrenia dan DM, disfungsi mitokondria, efek samping pengobatan antipsikotik, antidepresan, penstabil suasana hati berperan dalam hal tersebut.

A simple, rapid, selective, and reproducible HPLC method for Lurasidone Hydrochloride tablet release estimation has been developed and validated. An Agilent, X-Bridge column C18,150*4.6 mm, 3.5m was used to produce a symmetrical peak form at a regulated column temperature of 25°C with a flow rate of 1.5 mL/min, a mobile phase component of A and B in the ratio of 30:70, a run time of 14 minutes, and an isocratic elution. Mobile phase A is 0.2% ammonia in water with a pH of 8.5, and mobile phase B is 98:2 acetonitrile and water. At 232 nm, 25 μL sample solutions were injected. A two-stage acid-buffer dissolution condition simulated GI transit pH shift was used. The acid stage consisted of 500 mL of 0.1N HCl solution in each vessel USP apparatus-2 at 75 rpm for 60 minutes, followed by 500 mL of concentrated buffer media in each vessel and continued dissolution with the same parameters. Dissolution method suitability, specificity, precision, accuracy, linearity, robustness, and solution stability have been verified. From the validation data, a set of system appropriateness requirements for the approach have been created. The minimum level at which the technique was found to be sensitive to LH was1.2 µg/mL, 1.2 µg/mL to 18.0 µg/mL was the range for the method’s development, which was based on accuracy and linearity tests. The solutions passed a 24-hour stability test while being stored at room temperature.